"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Descriptor ID |
D020533
|
MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2000 | 8 | 3 | 11 |
2001 | 8 | 7 | 15 |
2002 | 13 | 7 | 20 |
2003 | 22 | 8 | 30 |
2004 | 17 | 12 | 29 |
2005 | 15 | 4 | 19 |
2006 | 20 | 10 | 30 |
2007 | 25 | 11 | 36 |
2008 | 24 | 11 | 35 |
2009 | 19 | 14 | 33 |
2010 | 13 | 12 | 25 |
2011 | 23 | 11 | 34 |
2012 | 20 | 11 | 31 |
2013 | 25 | 15 | 40 |
2014 | 27 | 12 | 39 |
2015 | 25 | 11 | 36 |
2016 | 31 | 8 | 39 |
2017 | 13 | 5 | 18 |
2018 | 15 | 8 | 23 |
2019 | 17 | 7 | 24 |
2020 | 16 | 11 | 27 |
2021 | 11 | 15 | 26 |
2022 | 6 | 13 | 19 |
2023 | 1 | 20 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review. Cancer Treat Rev. 2024 Jan; 122:102652.
-
Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 Nov; 54(11):654-659.
-
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
-
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.
-
Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2023 07 01; 141(7):658-666.
-
Effect of intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration on renal function. Nephrol Dial Transplant. 2023 Jun 30; 38(7):1770-1772.
-
Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells. Growth Factors. 2023 08; 41(3):140-151.
-
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
-
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219.